Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.
Beijing University of Chinese Medicine, Beijing, 100102, China.
Sci Rep. 2021 Apr 16;11(1):8402. doi: 10.1038/s41598-021-87812-9.
The Chinese herbal formula TiaoGanYiPi (TGYP) showed effective against chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) infection. Hence, we aimed to clarify the mechanisms and potential targets between TGYP and CHB. The active compounds and related putative targets of TGYP, and disease targets of CHB were obtained from the public databases. The key targets between TGYP and CHB were identified through the network construction and module analysis. The expression of the key targets was detected in Gene Expression Omnibus (GEO) dataset and normal hepatocyte cell line LO2. We first obtained 11 key targets which were predominantly enriched in the Cancer, Cell cycle and HBV-related pathways. And the expression of the key targets was related to HBV infection and liver inflammation verified in GSE83148 database. Furthermore, the results of real-time quantitative PCR and CCK-8 assay indicated that TGYP could regulate the expression of key targets including CCNA2, ABL1, CDK4, CDKN1A, IGFR and MAP2K1, and promote proliferation of LO2 cells. In coclusion, we identified the active compounds and key targets btween TGYP and CHB, and found that the TGYP might exhibite curative effect on CHB via promoting hepatocyte proliferation and inhibiting the liver inflammatory processes.
中药复方调肝益脾方(TGYP)对乙型肝炎病毒(HBV)感染引起的慢性乙型肝炎(CHB)有效。因此,我们旨在阐明 TGYP 与 CHB 之间的机制和潜在靶点。从公共数据库中获得了 TGYP 的活性化合物和相关潜在靶点以及 CHB 的疾病靶点。通过网络构建和模块分析确定了 TGYP 和 CHB 之间的关键靶点。在基因表达综合数据库(GEO)数据集和正常肝细胞系 LO2 中检测了关键靶点的表达。我们首先获得了 11 个主要富集在癌症、细胞周期和 HBV 相关途径中的关键靶点。并且在 GSE83148 数据库中验证了这些关键靶点的表达与 HBV 感染和肝炎症有关。此外,实时定量 PCR 和 CCK-8 检测结果表明,TGYP 可以调节包括 CCNA2、ABL1、CDK4、CDKN1A、IGFR 和 MAP2K1 在内的关键靶点的表达,并促进 LO2 细胞的增殖。总之,我们鉴定了 TGYP 与 CHB 之间的活性化合物和关键靶点,发现 TGYP 可能通过促进肝细胞增殖和抑制肝脏炎症过程对 CHB 发挥治疗作用。